Technologies
PDF


WARF: P06190US

Magnetic Resonance Imaging of Metabolites


INVENTORS -

Scott Reeder

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing in vivo metabolite imaging using paramagnetic labels such as hyperpolarized carbon-13.
OVERVIEWIn magnetic resonance imaging (MRI), tissue is scanned using magnetic fields that excite atoms and cause them to emit signals. These nuclear magnetic resonance (NMR) signals can be processed into an image using well-known reconstruction techniques.

An isotope called hyperpolarized carbon-13 has spurred interest in a variety of in vivo imaging applications such as vascular imaging and metabolic flux. In particular, C-13 labeled pyruvate and its metabolites (lactate and alanine) are of interest in oncology. The NMR spectrum of these three metabolites is relatively sparse, making them well-suited for chemical shift-based imaging methods like those commonly used to separate water and fat.

The standard method for imaging these C-13 isotopes requires large amounts of data: more than 60 NMR signals must be acquired at different echo times to resolve the spectral peaks of alanine and pyruvate. This makes for a difficult choice between scan time and spatial resolution.
THE INVENTIONA UW–Madison researcher has developed a method for imaging in vivo metabolites that dramatically reduces scan time.

The metabolite images are produced with an MRI system using a priori information about their resonant peaks and relative sizes. This reduces the amount of NMR data needed for proper spectral resolution. Also, the NMR signal can be modeled with an equation of relatively few unknowns. Using this model and NMR data acquired at a plurality of echo time (TE), the metabolite at each image pixel can be calculated and imaged.
APPLICATIONS
  • MR imaging of metabolites such as C-13 labeled pyruvate, lactate and alanine
KEY BENEFITS
  • Works 16 times faster than echo planar spectroscopic imaging (EPSI)
  • Substantially reduces the amount of NMR data needed to produce an image
  • Shortens scan time
STAGE OF DEVELOPMENTWork has focused on C-13 imaging, but the approach may be applied to chemical species with other nuclei.
Contact Information
For current licensing status, please contact Jeanine Burmania at jeanine@warf.org or 608-960-9846.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.